Immunofoco Biotech presents safety and efficacy data for IMC002 CAR-T targeting solid tumors at the 2024 ASCO Annual Meeting.

Immunofoco Biotech announced its clinical research data for two products, IMC001 and IMC002, targeting solid tumors, will be presented at the 2024 ASCO Annual Meeting. IMC002, an autologous CLDN18.2-targeting CAR-T, shows promising safety and efficacy data in treating CLDN18.2+ advanced solid tumors. The data will be presented in a poster session and online at the meeting from May 31 to June 4, 2024.